Plain-English translation of NCT04729543 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of immunotherapy where doctors take your own immune cells, engineer them to recognize and attack cancer cells, and put them back into your body. The engineered cells, called MC2 TCR T cells, are designed to find and destroy melanoma and head and neck cancers that have a specific protein on their surface. Before receiving the engineered cells, you'll receive two epigenetic drugs to help prepare your body for the treatment.
Many patients with advanced melanoma and head and neck cancer run out of standard treatment options, and their cancer continues to grow. This trial explores whether this new type of engineered cell therapy could help patients whose cancer has stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
You will first receive two weeks of epigenetic drugs (valproic acid and azacytidine) to prepare your tumors. After that, you'll receive an intravenous infusion of your engineered immune cells, followed by low-dose supportive medications for five days. The trial starts with small doses and gradually increases to find the safest and most effective dose. You'll have mandatory tumor biopsies and regular blood tests to monitor how well the treatment is working and watch for side effects. The study involves both a Phase 1 safety portion and a Phase 2 effectiveness portion with a total of 20 patients enrolled.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Netherlands